Monday, September 20, 2010

Novartis breaks through on meningitis vaccine

Novartis UK has made a breakthrough that could result in a vaccination for Meningitis B according to the UK Gazette. The recent clinical trial proved to be successful. Meningitis B is the most common form of the disease, and 6%, approximately 1,200 cases in the UK, result in death. The vaccine should be effective against three different strains of the disease.

Mr. Steve Dayman, chief executive of Meningitis UK, "The latest results from this study are very encouraging and we hope these promising developments will ultimately lead to a meningitis B vaccine that will be given to children in this country. This is obviously an exciting development, and one which our supporters across the country will welcome. While we sense that we’re getting closer to finding an elusive vaccine for meningitis B, there is still more work to be done."

This blog is co-posted with The Future of Biopharma Blog.

No comments:

Post a Comment